| Similar Articles |
|---|
 |
The Motley Fool
June 23, 2011
Brian Orelli |
In Addition, Our Drug Actually Rocks Pfizer and Bristol get good data on Eliquis.   |
The Motley Fool
July 27, 2011
Alexander Crawford |
Vertex Moving Closer to a Cure for Hepatitis C How do you think the treatment of hepatitis C will evolve? |
The Motley Fool
July 1, 2011
Alex Crawford |
3 Biotech Drugs With Promising Phase III Data, Moving Into FDA Review Do these drugs have a chance of FDA approval? |
The Motley Fool
November 30, 2011
Brian Orelli |
3 Things More Important to Pfizer Than Losing Lipitor It's not like we didn't see it coming. |
The Motley Fool
August 30, 2011
Brian Orelli |
Pfizer and Bristol-Myers Glide Through For Pfizer and Bristol-Myers Squibb's new atrial fibrillation treatment, Eliquis, the devil seems to have left the building. |
The Motley Fool
June 11, 2010
Brian Orelli |
Pfizer and Bristol Coagulate Against Clots Let's see how apixaban does against warfarin before we break out the "blockbuster" stamp. |
The Motley Fool
September 8, 2011
Arlene Weintraub |
Bristol-Pfizer Team on Alert as FDA Reviews Stroke-Prevention Drug From Rivals J&J and Bayer Who will come out ahead? |
The Motley Fool
November 15, 2010
Brian Orelli |
A Mega-Blockbuster Showdown Boehringer Ingelheim's Pradaxa was recently approved to treat patients with an erratic heartbeat, and Bayer and Johnson & Johnson have a second compound, Xarelto, that isn't far behind. |
The Motley Fool
November 30, 2011
Brian Orelli |
Drugmakers Bleeding Out That's not what blood thinners are supposed to do. |
The Motley Fool
April 6, 2011
Brian Orelli |
$1 Billion in Drug Sales Bleeds Out Don't feel too bad for Bayer and J&J though. |
The Motley Fool
July 5, 2011
Brian Orelli |
Drug Approved, But No Fireworks Yet The second FDA approval for Bayer and Johnson & Johnson's Xarelto is more important. |
The Motley Fool
October 26, 2010
Brian Orelli |
Where's the Growth in Big Pharma? The theme for the pharmaceutical industry's 2010 third-quarter earnings reports has been officially set: If you can't get it done through sales, just cut costs. |
The Motley Fool
November 22, 2010
Brian Orelli |
Pfizer's Mixed Bag Pfizer had a mixed bag of clinical trial results at the end of last week. And probably the company would have rather seen the results flip-flopped. |
The Motley Fool
August 26, 2010
Jordan DiPietro |
Pfizer's Dividends May Not Last Forever Pfizer, which operates in the pharmaceuticals industry, currently pays a dividend of 4.5%. But what's more important than the dividend itself is Pfizer's ability to keep that that cash rolling. |
The Motley Fool
July 10, 2007
Brian Orelli |
Sometimes, the Same Is Good Enough Bristol-Myers Squibb's new drug doesn't work better, but it's easier to take. Investors, take note. |
The Motley Fool
January 4, 2012
Rebecca Lipman |
Trading Strategy: 2012 Dogs of the Dow Are any of these names in your portfolio -- or on your watch list? |
The Motley Fool
August 30, 2010
Ilan Moscovitz |
Pfizer: Dividend Dynamo or Disaster? The stability and growth of Pfizer's dividend will depend on its ability to continue to develop and grow its pipeline of drugs and successfully integrate Wyeth. |
The Motley Fool
August 28, 2010
Todd Wenning |
Dividend Report Card: Johnson & Johnson Does this health-care titan's dividend pass the test? |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Acute Coronary Syndrome A new class of anticoagulants is competing to dethrone difficult-to-manage warfarin, long the sole option in the prevention of stroke and other bleeding complications in the 2.5 million US patients with atrial fibrillation. |
The Motley Fool
December 13, 2011
Brian Orelli |
Dividend? Buyback? Here's How to Get Both. But will there be enough to replenish the pipeline? |
The Motley Fool
May 3, 2006
Selena Maranjian |
When Dividends Are Dicey A hefty dividend yield isn't always something investors can count on. |
The Motley Fool
January 18, 2011
Russ Krull |
Keep It or Sweep It: Johnson & Johnson? Should the company be held or sold? |
The Motley Fool
January 12, 2012
Rebecca Lipman |
PC Shipments Falling: Will the Industry Ever Rebound? Microsoft may be hitting a rough spot. So, which other companies are at risk? |
The Motley Fool
July 29, 2011
Brian Orelli |
Bristol-Myers Grows in the Wrong Places Bristol-Myers has a solid quarter, but Plavix and currency movements aren't important. |
The Motley Fool
September 30, 2011
David Williamson |
This Week in Health Care Pharma news about Pfizer, AstraZeneca, and the multibillion-dollar battle to replace the maligned blood-thinner warfarin. |
The Motley Fool
June 8, 2011
Eben Esterhuizen |
High Yield: Highly Profitable Companies With Rising Dividends Will these companies help you you minimize the risk of investing in a dividend stock that's about to end its winning streak? |
The Motley Fool
August 3, 2011
Brian Orelli |
Ignore Pfizer's Financials for Now It's the pipeline that matters. |
The Motley Fool
February 25, 2011
Todd Wenning |
Dividend Report Card: Bristol-Myers Squibb How does the pharma giant's dividend stack up? |
The Motley Fool
September 7, 2011
Brian Orelli |
J&J and Bayer Head in Front of the Firing Squad An expanded indication for Xarelto seems unlikely. |
The Motley Fool
December 6, 2011
Alexander Crawford |
2012 Outlook: Analysts See Volatility Which stocks are poised to endure this period of volatility? |
The Motley Fool
August 13, 2010
Ilan Moscovitz |
Merck: Dividend Dynamo or Disaster? Just how safe is this dividend? |
The Motley Fool
January 18, 2012
Rebecca Lipman |
Publishing Stocks: Will Apple Lead the Textbook Digital Revolution? How do you think Apple's plan will affect the future of these companies? |
The Motley Fool
March 23, 2011
Todd Wenning |
Dividend Report Card: Pfizer Investors considering Pfizer as a dividend play should decide if the combination of 4% current yield and low- to mid-single-digit dividend growth potential is a better deal than other pharmaceutical shares are offering. |
The Motley Fool
September 9, 2011
Brian Orelli |
Firing Squad, It Was Not J&J and Bayer get through their advisory panel with minimal problems. |
The Motley Fool
January 12, 2012
Brian Orelli |
What to Look For From Pfizer in 2012 Leaner? Yes. Meaner? We'll see. |
The Motley Fool
January 3, 2011
Rex Moore |
Highest-Yielding Pharma Stocks (You Might Actually Want to Buy) How to combine high yield with low risk. |
The Motley Fool
June 30, 2010
Brian Orelli |
Is Bristol-Myers Squibb a Buy? Bristol-Myers is a better buy than Eli Lilly for one major reason: its resources. |
The Motley Fool
December 18, 2008
Brian Orelli |
Best Stock for 2009: Pfizer Pfizer's languishing stock price has made the company so much more attractive; it could see a breakout in 2009. |
The Motley Fool
June 11, 2008
Brian Lawler |
Dueling Fools: Pfizer Bear Is Pfizer ready for a comeback? The bearish opinion is that shares may be down, but the bleeding still isn't over. |
The Motley Fool
February 20, 2010
Selena Maranjian |
My Big Fat Dividends Stocks like these can plump up your portfolio. Stocks like Pfizer, Nokia, and Bristol-Myers Squibb can offer good yields. |
The Motley Fool
November 9, 2011
Alexander Crawford |
Dividend Ideas: 10 S&P 500 Stocks With Encouraging Profitability Do you think these stocks pay more reliable dividends because of their strong profitability trends? |
The Motley Fool
November 8, 2010
Brian Orelli |
No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective. |
The Motley Fool
June 11, 2008
Brian Orelli |
Dueling Fools: Pfizer Bull The bullish opinion on Pfizer is that this may be the best time to buy this stock. |
The Motley Fool
November 7, 2011
David Williamson |
Health-Care News You Can't Afford to Miss Highlighting the day's health-care stories: FDA approval for Johnson & Johnson... Inhibitex kept its streak of double-digit gains alive with another 14% surge today... 13% plunge for Optimer Pharmaceuticals... |
The Motley Fool
October 24, 2007
Selena Maranjian |
Meet the Dividend Achievers If you're looking for dividend-paying stocks, you need to know the Mergent Dividend Achievers. |
The Motley Fool
November 17, 2009
Brian Orelli |
Up 80%, It's Time to Sell Bristol-Myers to Mead Johnson: It's time to walk on your own. Investors will have an option of exchanging some or all of their Bristol-Myers shares for shares in Mead Johnson for a slight discount |
The Motley Fool
May 19, 2011
Esterhuizen & Sellitti |
Dividend Boost: 3 High Yield Stocks That Short-Sellers Won't Touch Are short-sellers right about these stocks?: Intersections... China Mobile Limited... Alto Palermo... |
The Motley Fool
September 2, 2011
Becca Lipman |
Industrial Stocks: Mixed News on the Future of U.S. Factories Interested in keeping tabs on the future of factories? |
The Motley Fool
June 8, 2011
Eben Esterhuizen |
Profit Payouts: Companies Offering Sustainable Growth While Boosting Dividends These companies are firing on all cylinders: Republic Bancorp... First Commonwealth Financial... Commerce Bancshares... Hormel Foods... |
The Motley Fool
September 30, 2011
Brian Orelli |
Pfizer's Fungus Failure A combination treatment doesn't work. |
